Evidence map›Paper›PMID 33615021›Full record

ArticleJMA journal2019

Establishment of Integrated Biobank for Precision Medicine and Personalized Healthcare: The Tohoku Medical Megabank Project.

Nobuo Fuse, Mika Sakurai-Yageta, Fumiki Katsuoka, Inaho Danjoh, Ritsuko Shimizu, Gen Tamiya, Fuji Nagami, Hiroshi Kawame, Shinichi Higuchi, Kengo Kinoshita and 2 more

Abstract read
In one paragraph

Article in JMA journal, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers.

0numbers the graph read from it
0cells of the map it votes in
26citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

26 citing papers in PubMed.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Review
  15. Article
  16. Article
  17. AHR and NRF2 in Skin Homeostasis and Atopic Dermatitis.Antioxidants (Basel, Switzerland) · 2022
    Review
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Nobuo FuseDepartment of Integrative Genomics, Tohoku Medical Megabank Organization, Tohoku University, Sendai, Japan.
Mika Sakurai-YagetaDepartment of Education and Training, Tohoku Medical Megabank Organization, Tohoku University, Sendai, Japan.
Fumiki KatsuokaDepartment of Integrative Genomics, Tohoku Medical Megabank Organization, Tohoku University, Sendai, Japan.
Inaho DanjohDepartment of Integrative Genomics, Tohoku Medical Megabank Organization, Tohoku University, Sendai, Japan.
Ritsuko ShimizuDepartment of Integrative Genomics, Tohoku Medical Megabank Organization, Tohoku University, Sendai, Japan.
Gen TamiyaDepartment of Integrative Genomics, Tohoku Medical Megabank Organization, Tohoku University, Sendai, Japan.
Fuji NagamiDepartment of Public Relations and Planning, Tohoku Medical Megabank Organization, Tohoku University, Sendai, Japan.
Hiroshi KawameDepartment of Education and Training, Tohoku Medical Megabank Organization, Tohoku University, Sendai, Japan.
Shinichi HiguchiDepartment of Public Relations and Planning, Tohoku Medical Megabank Organization, Tohoku University, Sendai, Japan.
Kengo KinoshitaDepartment of Integrative Genomics, Tohoku Medical Megabank Organization, Tohoku University, Sendai, Japan.
Shigeo KureDepartment of Integrative Genomics, Tohoku Medical Megabank Organization, Tohoku University, Sendai, Japan.
Masayuki YamamotoDepartment of Integrative Genomics, Tohoku Medical Megabank Organization, Tohoku University, Sendai, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The Tohoku Medical Megabank (TMM) project was established to provide creative reconstruction of the Tohoku area that suffered from a huge earthquake and ensuing tsunami (the Great East Japan Earthquake, GEJE). TMM aims to establish two large-scale genome cohorts and an integrated biobank managing biospecimen and related information. It supports community medicine by establishing next-generation medical systems through a combination of the prospective genome cohort studies with a total of 150,000 participants and genomic medicine. The strategies for genome analyses in TMM are to develop an elaborate genome reference panel by means of high-fidelity Japanese whole-genome sequence, to design custom single nucleotide polymorphism (SNP) arrays based on the reference panel, and to obtain genotype data for all the TMM cohort participants subsequently. Disease-associated genomic information and omics data, including metabolomics and microbiome analysis, provide an essential platform for precision medicine and personalized healthcare (PHC). Ethical, legal, and social issues (ELSI) and education are important for implementing genomic medicine. The major considerations of ELSI regarding each participant of the cohort studies are the respect for the autonomy and the protection of privacies. Moreover, developing and provide human resources not only for the TMM project but also for the social implementation of precision medicine and PHC is required. We started a pilot study of the return of genomic results for familial hypercholesterolemia (FH) as a target disease. TMM aims to establish solid platforms that support precision medicine and PHC based on the genomic and omics information and environmental and lifestyle factors of the individuals, which is one of the most advanced medical care beyond the evidenced-based medicine in the near future.

Indexed as

clinical sequencinggenomic medicineJaponica arraypersonalized healthcareprecision medicineTohoku Medical Megabank Projectwhole-genome reference panel

Identifiers

PMID33615021
PMCPMC7889718

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.